Morepen Laboratories Ltd share price ticked higher by 1.19% to Rs 57.68 after the company's net profit soared by 258.92% to Rs 56.35 crore, while revenue from operations gained 17.62% to Rs 570.13 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.75 lakh crore, rising 5.95%. It has improved by 1.51% over last one week and advanced by 11.59% in last one month while the market capitalization of Morepen Laboratories Ltd has marginally improved by 4.32% and 32.41% in the same period respectively. Profit before tax (PBT) of Morepen Laboratories Ltd stood at Rs 74.53 crore in Q2 FY26, jumping 380.22% year-on-year, and surging by 220.01% quarter-on-quarter. EBITDA came in at Rs 77 crore, rallying 291.30% YoY and expanding by 383.80% sequentially. Total expenses inched up 6.42% to Rs 495.94 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 328.38 crore, increasing 13.01% YoY, while employee benefits expense was at Rs 62.44 crore, easing 6.26% YoY. For the TTM ended FY26, revenue from operations posted a slight growth of 7.17% to Rs 1811.58 crore, while net profit saw a strong growth of 22.15% to Rs 118.02 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 13917% to Rs 155.71 crore, and PBT registered a growth of 14.54% to Rs 155.11 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 32.06 crore in FY26, as against Rs 73.37 crore in FY25. Morepen Laboratories Ltd slipped 0.14% in last one year, outperforming the benchmark BSE Sensex which has softened by 2.94% during the same period.
